HSBC Turns More Bullish on Amgen (AMGN) into 2026

Core Insights - Amgen Inc. (NASDAQ:AMGN) is recognized as one of the 12 Best Dogs of the Dow to invest in [1] - HSBC has raised its price target for Amgen to $425 from $381, maintaining a Buy rating, reflecting a positive outlook for the pharma sector heading into 2026 [2] - The FDA has approved UPLIZNA for treating generalized myasthenia gravis, providing a new treatment option with a dosing schedule that allows for six months of treatment-free time [2][3] Company Overview - Amgen Inc. focuses on discovering, developing, manufacturing, and delivering innovative medicines, particularly in the field of biologics, addressing serious conditions such as cancer, inflammation, heart disease, and rare disorders [4]